<DOC>
	<DOCNO>NCT01824121</DOCNO>
	<brief_summary>There evidence suggest stem cell harvest bone marrow transplant brain may effective slow progression parkinsonism . Mesenchymal stem cell able produce growth factor provide support diseased nervous cell . In study mesenchymal stem cell harvest bone marrow , cultivate test tube multiply infused artery supply blood brain 20 patient suffer rare form parkinsonism , Progressive Supranuclear Palsy . Each patient undergo two infusion , one stem cell one without , interval 6 month . The sequence two infusion assign randomly ; patient assessor know sequence ( double-blind ) . Patients followed-up 1 year last infusion , regular assessment assess safety , efficacy motor cognitive function , effect brain neuroimaging technique . The study preliminary phase 5 patient give stem cell therapy alone , design ass safety</brief_summary>
	<brief_title>Clinical Trial Evaluate Bone Marrow Stem Cell Therapy PSP , Rare Form Parkinsonism</brief_title>
	<detailed_description />
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>diagnosis 'probable Progressive Supranuclear Palsy Richardson 's disease subtype ' accord current diagnostic criterion ( Litvan et al . 1996 2003 ) age onset least 40 year ; disease duration 12 month 8 year ; supranuclear ophthalmoplegia ; postural instability fall within 3 year disease onset positive MRI PSP criterion ( Quattrone et al , 2008 ) Stable pharmacological treatment least 90 day Lack response chronic levodopa ( least 12month treatment ) . Able stand upright posture without assistance least 30 second Written inform consent ( include video tap ) Idiopathic Parkinson 's disease ; Cerebellar ataxia Symptomatic autonomic dysfunction Evidence neurological disease could explain sign ; History repeat stroke stepwise progression parkinsonian feature ; History major stroke ; Any history severe repeat head injury ; A history encephalitis ; A history neuroleptic use prolong period time within past 6 month ; Streetdrug relate parkinsonism ; Significant neurological disease CTscan/MRI ; Oculogyric crises ; Major sign corticobasal degeneration ; Signs Lewy body disease ; Other lifethreatening disease likely interfere main outcome measure ; Any clinically significant laboratory abnormality , exception cholesterol , triglyceride glucose ; Renal failure ( serum creatinine 300 mM/l ) ; Transaminase elevation twice upper limit normal ; Any concomitant disorder associate bone marrow function impairment Any concomitant disorder require chronic treatment immunosuppressor , antiinflammatory agent , and/or growth factor dementia ( MMSE &lt; 24 accord Folstein 1975 define accord DSMIV TR criterion ) disorder could interfere evaluation treatment could make intraarterial infusion inadvisable feature , accord investigator , could reduce adherence protocol procedure prevent rapid access case emergency ; woman childbearing age participation another clinical trial experimental treatment last 30 day brain MRI evidence severe vascular abnormality , spaceoccupying lesion normal pressure hydrocephalus</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Progressive Supranuclear palsy</keyword>
	<keyword>stem cell therapy</keyword>
</DOC>